Browsing by Author Cuzick, Jack

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2014Assessing and managing breast cancer risk: Clinicians’ current practice and future needsButow, Phyllis; Antoniou, Antonis C.; Bickerstaffe, Adrina; Collins, Ian; Cuzick, Jack; Emery, Jon; Hopper, John; Keogh, Louise; Mann, Bruce Gregory; Phillips, Kelly-Anne; Pirotta, Marie; Steel, Emma; Trainer, Alison; PsychologyAssessing and managing breast cancer risk: Clinicians’ current practice and future needs, The Breast, vol.23, 5, 2014,pp 644-650
2016iPrevent: a tailored, web-based, decision support tool for breast cancer risk assessment and managementButow, Phyllis; Antoniou, Antonis; Bickerstaffe, Adrian; Bressel, Mathias; Collins, Ian; Cuzick, Jack; Emery, Jon; Hopper, John L.; Keogh, Louise; Maddumarachchi, Sanjaya; Mann, G Bruce; Phillips, Kelly-Anne; Ranaweera, Thilina; Steel, Emma; Trainer, Alison; Weideman, Prue C; PsychologyiPrevent: a tailored, web-based, decision support tool for breast cancer risk assessment and management, Breast Cancer Research and Treatment, vol.156, 1, 2016,pp 171-182
2015Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial.Byth Wilson, Karen; Clarke, Christine; Graham, Justine (Dinny); Hilton, Heidi; Howe, Chris; Mote, Patricia; Cuzick, Jack; Dowsett, Mitch; Forgez, Patricia; Gompell, Anne; Hugol, Danielle; Sestak, Ivana; NH&MRC Clinical Trials Centre; Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Westmead Institute for Medical ResProgesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial., Breast Cancer Research and Treatment, vol.151, 2, 2015,pp 309-318